fda2WASHINGTON, D.C. (5/15/13) - The U.S. Food and Drug Administration today approved Xofigo (radium Ra 223 dichloride) to treat men with symptomatic late-stage (metastatic) castration-resistant prostate cancer that has spread to bones but not to other organs. It is intended for men whose cancer has spread after receiving medical or surgical therapy to lower testosterone.

Prostate cancer forms in a gland in the male reproductive system found below the bladder and in front of the rectum. The male sex hormone testosterone stimulates the prostate tumors to grow. According to the National Cancer Institute, an estimated 238,590 men will be diagnosed with prostate cancer and 29,720 will die from the disease in 2013.

Xofigo is being approved more than three months ahead of the product’s prescription drug user fee goal date of Aug. 14, 2013, the date the agency was scheduled to complete review of the drug application. The FDA reviewed Xofigo under the agency’s priority review program, which provides for an expedited review of drugs that appear to provide safe and effective therapy when no satisfactory alternative therapy exists, or offer significant improvement compared to marketed products.

“Xofigo binds with minerals in the bone to deliver radiation directly to bone tumors, limiting the damage to the surrounding normal tissues,” said Richard Pazdur, M.D., director of the Office of Hematology and Oncology Products in the FDA’s Center for Drug Evaluation and Research. “Xofigo is the second prostate cancer drug approved by the FDA in the past year that demonstrates an ability to extend the survival of men with metastatic prostate cancer.”

In August 2012, the FDA approved Xtandi to treat men with metastatic castration-resistant prostate cancer that has spread or recurred, even with medical or surgical therapy to minimize testosterone. Xtandi is approved for patients who have previously been treated the chemotherapy drug docetaxel.

Xofigo’s safety and effectiveness were evaluated in a single clinical trial of 809 men with symptomatic castration-resistant prostate cancer that spread to bones but not to other organs. Patients were randomly assigned to receive Xofigo or a placebo plus best standard of care.

The study was designed to measure overall survival. Results from a pre-planned interim analysis showed men receiving Xofigo lived a median of 14 months compared to a median of 11.2 months for men receiving placebo. An exploratory updated analysis conducted later in the trial confirmed Xofigo’s ability to extend overall survival.

The most common side effects reported during clinical trials in men receiving Xofigo were nausea, diarrhea, vomiting and swelling of the leg, ankle or foot. The most common abnormalities detected during blood testing included low levels of red blood cells (anemia), lymphocytes (lymphocytopenia), white blood cells (leukopenia), platelets (thrombocytopenia) and infection-fighting white blood cells (neutropenia).

Xofigo is marketed by Wayne, N.J.-based Bayer Pharmaceuticals. Xtandi is co-marketed by Astellas Pharma U.S., Inc. of Northbrook, Ill., and Medivation, Inc. of San Francisco, Calif.
 
SurfKY News
Information provided by the United States Food and Drug Administration

© Copyright 2015 SurfKY News Group, Inc. All rights reserved. This material may not be published, broadcast, or rewritten without permission. SurfKY News encourages you to share this story on social media.

springhour

In Other News...

Lady Trojans Oust University Heights, Move on to Semis

MARION, Ky. (3/5/15) — Webster County is one of only four girls' basketball teams remaining in the Second Region Girls'… Read More

No Downtown Trolley Today, March 5

OWENSBORO, Ky. (3/5/15) — There will be no downtown trolley service today, March 5, 2015 due to inclement weather. For… Read More

Most Read This Week

March 02, 2015 9555

Madisonville Teen Faces Numerous Drug Charges

in Local (Hopkins) Top News by Madisonville Police Department/Hopkins County Detention Center
March 03, 2015 5806

Three Arrested during Traffic Stop

in Local (Hopkins) Top News by Madisonville Police Department/Hopkins County Detention Center
March 05, 2015 4365

State of Emergency Declared for Hopkins County

in Local (Hopkins) Top News by Leslie Curneal
March 05, 2015 4035

UPDATE: I-24 Open Between 50-45 MM

in Top News For All Sites Touching Hopkins by Keith Todd
March 02, 2015 3763

HCSO, MPD Join to Bust Alleged Drug Trafficking…

in Local (Hopkins) Top News by Hopkins County Sheriff's Office
March 03, 2015 3665

Sacramento Man Charged with Rape, Sodomy

in Local (Muhlenberg) Top News by Charles W. Riley II, SurfKY News

Most Read This Month

February 12, 2015

UPDATE: Name of Pennyrile Fatality Officially…

in Top News For All Sites Touching Hopkins by Doreen Dennis, SurfKY News
February 16, 2015

UPDATE: State of Emergency Declared for Kentucky

in Local (Hopkins) Top News by Rita Dukes Smith, SurfKY News Director

Stories Trending Today

March 05, 2015 4365

State of Emergency Declared for Hopkins County

in Local (Hopkins) Top News by Leslie Curneal
March 05, 2015 4035

UPDATE: I-24 Open Between 50-45 MM

in Top News For All Sites Touching Hopkins by Keith Todd
March 05, 2015 2468

Deep Snowfall Stalls Western Kentucky

in Top News For All Sites by SurfKY News
March 05, 2015 1761

Muhlenberg Issues State of Emergency Under…

in Local (Muhlenberg) Top News by Paul McRee, SurfKY News
March 05, 2015 1306

Dyno Nobel Makes $1,600 Donation to Want Not…

in Top News For All Sites Touching Hopkins by Tammy Holloway, SurfKY News
March 05, 2015 1280

Governor Declares State of Emergency

in Top News For All Sites by Office of the Governor
March 04, 2015 1105

I-24 Traffic Backed Up From 46-65 MM Due to…

in Local (Lakes) Top News by Keith Todd
March 04, 2015 954

Gov. Beshear Warns Kentuckians to Prepare for…

in General News For All Sites by Office of the Governor
March 05, 2015 952

KYDOT Believes as Many as 200 Vehicles Stuck on…

in General News For All Sites by Keith Todd
March 05, 2015 927

UPDATE - Lady Mustangs Trample Lady Tigers in…

in Local (Muhlenberg) Top News by Steve LeMaster